[1]
|
A. Jemal, T. Murray and E. Ward, “Cancer Statistics,” CA: A Cancer Journal for Clinicians, Vol. 55, No. 1, 2005, pp. 10-30. doi:10.3322/canjclin.55.1.10
|
[2]
|
Instituto Nacionall de Oncologia, “Manual de Oncologia Médica,” Procedimentos Medico Quirurgicos, 2a Edición, McGraw Hill, Boston, 2002.
|
[3]
|
L. M. Hock, J. Lynch and K. C. Balaji, “Increasing Incidences of all Stages of Kidney Cancer in the United States: An Analysis of Surveillance, Epidemiology and End Results Program Data,” Journal of Urology, Vol. 167, No. 1, 2002, pp. 57-60.
doi:10.1016/S0022-5347(05)65382-7
|
[4]
|
S. Ramsay and M. Aithkinson, “Treatment of Renal Cell Carcinoma: Are We beyond the Cytokine Era?” Nature Clinical Practice Urology, Vol. 3, No. 9, 2006, pp. 478-484. doi:10.1038/ncpuro0581
|
[5]
|
E. Soto-Vega, C. Arroyo, Y. Richaud-Patin, M. García-Carrasco, L. G. Vázquez-Lavista and L. Llorente “P- Glycoprotein Activity in Renal Clear Cell Carcinoma,” Urologic Oncology, Vol. 27, No. 4, 2009, pp. 363-366.
doi:10.1016/j.urolonc.2008.01.011
|
[6]
|
R. J. Motzer, T. E. Hutson, P. Tomczak, et al., “Sunitinib versus Interferon Alpha in Metastatci Renal Cell Carcinoma,” The New England Journal of Medicine, Vol. 356, No. 2, 2007, pp. 115-124. doi:10.1056/NEJMoa065044
|
[7]
|
B. Escudier, “Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma,” The New England Journal of Medicine, Vol. 356, No. 2, 2007, pp. 125-134.
doi:10.1056/NEJMoa060655
|
[8]
|
J. C. Young, L. Haworth, R. M. Sherry, et al., “A Randomized Trial of Bevacizumav an Antivascular Endothelial Growth Factor Antibody for Metastatic Renal Cell Cancer,” The New England Journal of Medicine, Vol. 349, No. 5, 2003, pp. 427-434.
doi:10.1056/NEJMoa021491
|
[9]
|
C. Wood, et al., “Neoadjuvant (Presurgical) Therapy for Renal Cell Carcinoma: A New Treatment Paradigm for Locally Advanced and Metastatic Disease,” Cancer, Vol. 115, No. S10, 2009, pp. 2355-2360.
doi:10.1002/cncr.24240
|
[10]
|
National Comprehensive Cancer Network, “Clinical Practice Guidelines in OncologyTM,” Kidney Cancer, V2, 2010. www.nccn.org
|
[11]
|
F. Di siverio, A. Sciarra, U. Parente, A. Andrea, M. Von Heland, V. Panebianco and R. Passariello, “Neoadjuvant Therapy with Sorafenib in Advanced Renal Cell Carcinoma with Vena Cava Extension Submitted to Radical Nephrectomy,” Urologia Internationalis, Vol. 80, No. 4, 2008, pp. 451-453.
|
[12]
|
L. C. Harshman, R. J. Yu, G. I. Allen, S. Srinvas, H. S. Gill and B. I. Chung, “Surgical Outcomes and Complications Associated with Presurgical Tyrosine Kinase Inhibition for Advanced Renal Cell Carcinoma (RCC),” Urologic Oncology, 24 February 2011.
|
[13]
|
G. Mickisch, J. Carballido, S. Hellsten, H. Schulze, H. Mensink and European Association of Urology, “Guidelines on Renal Cell Cancer,” European Urology, Vol. 40, No. 3, 2001, pp. 252-255. doi:10.1159/000049783
|